Tottori Univ Oncolytic Virus Breakthrough | AcademicJobs
Tottori University researchers unveil FUVAC121, a fusogenic oncolytic vaccinia virus achieving 72% complete remission in metastatic models via immune activation.
No reviews yet. Be the first to rate Motomu!
Motomu Nakatake is an Assistant Professor in the Division of Genomic Medicine, Faculty of Medicine, School of Medicine at Tottori University. He completed undergraduate studies in the Faculty of Medicine School of Life Sciences at Tottori University from 2010 to 2014. He pursued further graduate education at Tottori University Graduate School of Medical Sciences Institute of Regenerative Medicine and Biofunction from 2016 to 2019, with additional studies from 2014 to 2016.
His research involves oncolytic vaccinia viruses, including work on cell-cell fusion and immunostimulatory cytokines in cancer therapy applications. He has contributed to publications examining the anticancer potential of oncolytic viruses enhanced by histone deacetylase inhibitors and the impact of cell-cell fusion mechanisms on systemic antitumor immune responses. Nakatake collaborates on projects developing fusogenic oncolytic vaccinia viruses for modulating the tumor microenvironment.
Tottori University researchers unveil FUVAC121, a fusogenic oncolytic vaccinia virus achieving 72% complete remission in metastatic models via immune activation.
Photo by Mufid Majnun on Unsplash
Photo by Shubham Sharan on Unsplash
Photo by Shubham Sharan on Unsplash
Photo by Evan Marvell on Unsplash
Photo by Markus Winkler on Unsplash
Photo by Patrick Robert Doyle on Unsplash
Photo by Brandi Redd on Unsplash
Have a story or a research paper to share? Become an Expert Academic Contributor and publish your work on AcademicJobs.com.
Write news and research articles as a expert academic in your field publish your work on AcademicJobs.com
